$ News

High Growth Tech Stocks in the US for April 2025

3 Growth Companies Insiders Are Betting On

Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023)

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shift From Loss To Profit

Sector Update: Health Care Stocks Decline Late Afternoon

Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties

Top India Drugmaker to Buy US-Based Checkpoint for $355 Million

Sun Pharma agrees to acquire Checkpoint Therapeutics

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million

Sun Pharma to Acquire Checkpoint Therapeutics

Checkpoint Therapeutics: Pivoting From Approval To Gutsy Next Shot On Goal

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%

Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)